A mutant-cell library for systematic analysis of heparan sulfate structure–function relationships


Heparan sulfate (HS) is a complex linear polysaccharide that modulates a wide range of biological functions. Elucidating the structure–function relationship of HS has been challenging. Here we report the generation of an HS-mutant mouse lung endothelial cell library by systematic deletion of HS genes expressed in the cell. We used this library to (1) determine that the strictly defined fine structure of HS, not its overall degree of sulfation, is more important for FGF2–FGFR1 signaling; (2) define the epitope features of commonly used anti-HS phage display antibodies; and (3) delineate the fine inter-regulation networks by which HS genes modify HS and chain length in mammalian cells at a cell-type-specific level. Our mutant-cell library will allow robust and systematic interrogation of the roles and related structures of HS in a cellular context.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Expression of HS biosynthetic and remodeling genes in MLECs.
Fig. 2: HS expression in the generated mutant MLEC lines.
Fig. 3: Effects of HS structure alteration on FGF2 binding and downstream Erk1/2 activation.
Fig. 4: Binding of anti-HS phage display antibody to mutant HS on the endothelial cell surface.
Fig. 5: Inter-regulation among HS modification and remodeling genes in HS fine structure expression.

Data availability

All data generated or analyzed during this study are included in this article and/or its associated Supplementary Information files. The raw data files are available from the corresponding author upon request. Source data for Figs. 15 and Supplementary Figs. 3, 5, and 10 are available online.


  1. 1.

    Bernfield, M. et al. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68, 729–777 (1999).

    CAS  PubMed  Google Scholar 

  2. 2.

    Esko, J. D. & Lindahl, U. Molecular diversity of heparan sulfate. J. Clin. Invest. 108, 169–173 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Wang, L., Brown, J. R., Varki, A. & Esko, J. D. Heparin’s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J. Clin. Invest. 110, 127–136 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Bishop, J. R., Schuksz, M. & Esko, J. D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446, 1030–1037 (2007).

    CAS  PubMed  Google Scholar 

  5. 5.

    Xu, D. & Esko, J. D. Demystifying heparan sulfate-protein interactions. Annu. Rev. Biochem. 83, 129–157 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Jemth, P. et al. Biosynthetic oligosaccharide libraries for identification of protein-binding heparan sulfate motifs. Exploring the structural diversity by screening for fibroblast growth factor (FGF)1 and FGF2 binding. J. Biol. Chem. 277, 30567–30573 (2002).

    CAS  PubMed  Google Scholar 

  7. 7.

    Kreuger, J. et al. Fibroblast growth factors share binding sites in heparan sulphate. Biochem. J. 389, 145–150 (2005).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Kamimura, K. et al. Specific and flexible roles of heparan sulfate modifications in Drosophila FGF signaling. J. Cell Biol. 174, 773–778 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Lindahl, U. & Li, J. P. Interactions between heparan sulfate and proteins—design and functional implications. Int. Rev. Cell Mol. Biol. 276, 105–159 (2009).

    PubMed  Google Scholar 

  10. 10.

    Kraushaar, D. C., Yamaguchi, Y. & Wang, L. Heparan sulfate is required for embryonic stem cells to exit from self-renewal. J. Biol. Chem. 285, 5907–5916 (2010).

    CAS  PubMed  Google Scholar 

  11. 11.

    Qiu, H. et al. Quantitative phosphoproteomics analysis reveals broad regulatory role of heparan sulfate on endothelial signaling. Mol. Cell. Proteomics 12, 2160–2173 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Kraushaar, D. C. et al. Heparan sulfate facilitates FGF and BMP signaling to drive mesoderm differentiation of mouse embryonic stem cells. J. Biol. Chem. 287, 22691–22700 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Faham, S., Hileman, R. E., Fromm, J. R., Linhardt, R. J. & Rees, D. C. Heparin structure and interactions with basic fibroblast growth factor. Science 271, 1116–1120 (1996).

    CAS  PubMed  Google Scholar 

  14. 14.

    Schlessinger, J. et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6, 743–750 (2000).

    CAS  PubMed  Google Scholar 

  15. 15.

    Turnbull, J. E., Fernig, D. G., Ke, Y., Wilkinson, M. C. & Gallagher, J. T. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J. Biol. Chem. 267, 10337–10341 (1992).

    CAS  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Ashikari-Hada, S. et al. Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J. Biol. Chem. 279, 12346–12354 (2004).

    CAS  PubMed  Google Scholar 

  17. 17.

    Guimond, S. E. & Turnbull, J. E. Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides. Curr. Biol. 9, 1343–1346 (1999).

    CAS  PubMed  Google Scholar 

  18. 18.

    Jastrebova, N. et al. Heparan sulfate-related oligosaccharides in ternary complex formation with fibroblast growth factors 1 and 2 and their receptors. J. Biol. Chem. 281, 26884–26892 (2006).

    CAS  PubMed  Google Scholar 

  19. 19.

    van Kuppevelt, T. H., Dennissen, M. A., van Venrooij, W. J., Hoet, R. M. & Veerkamp, J. H. Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J. Biol. Chem. 273, 12960–12966 (1998).

    CAS  PubMed  Google Scholar 

  20. 20.

    Dennissen, M. A. et al. Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies. J. Biol. Chem. 277, 10982–10986 (2002).

    CAS  PubMed  Google Scholar 

  21. 21.

    Thompson, S. M. et al. Heparan sulfate phage display antibodies identify distinct epitopes with complex binding characteristics: insights into protein binding specificities. J. Biol. Chem. 284, 35621–35631 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Ten Dam, G. B. et al. 3-O-sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody HS4C3. J. Biol. Chem. 281, 4654–4662 (2006).

    PubMed  Google Scholar 

  23. 23.

    Jenniskens, G. J., Oosterhof, A., Brandwijk, R., Veerkamp, J. H. & van Kuppevelt, T. H. Heparan sulfate heterogeneity in skeletal muscle basal lamina: demonstration by phage display-derived antibodies. J. Neurosci. 20, 4099–4111 (2000).

    CAS  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Kurup, S. et al. Characterization of anti-heparan sulfate phage display antibodies AO4B08 and HS4E4. J. Biol. Chem. 282, 21032–21042 (2007).

    CAS  PubMed  Google Scholar 

  25. 25.

    Deligny, A. et al. NDST2 (N-deacetylase/N-sulfotransferase-2) enzyme regulates heparan sulfate chain length. J. Biol. Chem. 291, 18600–18607 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Bai, X., Wei, G., Sinha, A. & Esko, J. D. Chinese hamster ovary cell mutants defective in glycosaminoglycan assembly and glucuronosyltransferase I. J. Biol. Chem. 274, 13017–13024 (1999).

    CAS  PubMed  Google Scholar 

  27. 27.

    Esko, J. D., Rostand, K. S. & Weinke, J. L. Tumor formation dependent on proteoglycan biosynthesis. Science 241, 1092–1096 (1988).

    CAS  PubMed  Google Scholar 

  28. 28.

    Esko, J. D., Stewart, T. E. & Taylor, W. H. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc. Natl. Acad. Sci. USA 82, 3197–3201 (1985).

    CAS  Google Scholar 

  29. 29.

    Zhang, L., Lawrence, R., Frazier, B. A. & Esko, J. D. in Methods in Enzymology Vol. 416 (ed Fukuda, M.) 205–221 (Academic Press, New York, 2006).

  30. 30.

    Xu, X. et al. The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. Nat. Biotechnol. 29, 735–741 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Wijelath, E. et al. Multiple mechanisms for exogenous heparin modulation of vascular endothelial growth factor activity. J. Cell. Biochem. 111, 461–468 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Zhang, B. et al. Heparan sulfate deficiency disrupts developmental angiogenesis and causes congenital diaphragmatic hernia. J. Clin. Invest. 124, 209–221 (2014).

    CAS  PubMed  Google Scholar 

  33. 33.

    Qiu, H., Xiao, W., Yue, J. & Wang, L. Heparan sulfate modulates Slit3-induced endothelial cell migration. Methods Mol. Biol. 1229, 549–555 (2015).

    CAS  PubMed  Google Scholar 

  34. 34.

    Zhang, B. et al. Repulsive axon guidance molecule Slit3 is a novel angiogenic factor. Blood 114, 4300–4309 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Nakato, H. & Kimata, K. Heparan sulfate fine structure and specificity of proteoglycan functions. Biochim. Biophys. Acta 1573, 312–318 (2002).

    CAS  PubMed  Google Scholar 

  36. 36.

    Habuchi, H., Habuchi, O. & Kimata, K. Sulfation pattern in glycosaminoglycan: does it have a code? Glycoconj. J. 21, 47–52 (2004).

    CAS  PubMed  Google Scholar 

  37. 37.

    Maccarana, M., Casu, B. & Lindahl, U. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J. Biol. Chem. 268, 23898–23905 (1993).

    CAS  PubMed  Google Scholar 

  38. 38.

    Lensen, J. F. et al. Localization and functional characterization of glycosaminoglycan domains in the normal human kidney as revealed by phage display-derived single chain antibodies. J. Am. Soc. Nephrol. 16, 1279–1288 (2005).

    CAS  PubMed  Google Scholar 

  39. 39.

    Powell, A. K., Yates, E. A., Fernig, D. G. & Turnbull, J. E. Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches. Glycobiology 14, 17R–30R (2004).

    CAS  PubMed  Google Scholar 

  40. 40.

    Li, J. P. & Kusche-Gullberg, M. Heparan sulfate: biosynthesis, structure, and function. Int. Rev. Cell Mol. Biol. 325, 215–273 (2016).

    CAS  PubMed  Google Scholar 

  41. 41.

    Bai, X. & Esko, J. D. An animal cell mutant defective in heparan sulfate hexuronic acid 2-O-sulfation. J. Biol. Chem. 271, 17711–17717 (1996).

    CAS  PubMed  Google Scholar 

  42. 42.

    Merry, C. L. et al. The molecular phenotype of heparan sulfate in the Hs2st −/− mutant mouse. J. Biol. Chem. 276, 35429–35434 (2001).

    CAS  PubMed  Google Scholar 

  43. 43.

    Townley, R. A. & Bülow, H. E. Genetic analysis of the heparan modification network in Caenorhabditis elegans. J. Biol. Chem. 286, 16824–16831 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Inatani, M., Irie, F., Plump, A. S., Tessier-Lavigne, M. & Yamaguchi, Y. Mammalian brain morphogenesis and midline axon guidance require heparan sulfate. Science 302, 1044–1046 (2003).

    CAS  PubMed  Google Scholar 

  45. 45.

    Wang, L., Fuster, M., Sriramarao, P. & Esko, J. D. Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat. Immunol. 6, 902–910 (2005).

    CAS  PubMed  Google Scholar 

  46. 46.

    Forsberg, E. et al. Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature 400, 773–776 (1999).

    CAS  PubMed  Google Scholar 

  47. 47.

    Stanford, K. I. et al. Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance. J. Biol. Chem. 285, 286–294 (2010).

    CAS  PubMed  Google Scholar 

  48. 48.

    Izvolsky, K. I., Lu, J., Martin, G., Albrecht, K. H. & Cardoso, W. V. Systemic inactivation of Hs6st1 in mice is associated with late postnatal mortality without major defects in organogenesis. Genesis 46, 8–18 (2008).

    CAS  PubMed  Google Scholar 

  49. 49.

    Sugaya, N., Habuchi, H., Nagai, N., Ashikari-Hada, S. & Kimata, K. 6-O-sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signalings in culture. J. Biol. Chem. 283, 10366–10376 (2008).

    CAS  PubMed  Google Scholar 

  50. 50.

    Tran, T. H., Shi, X., Zaia, J. & Ai, X. Heparan sulfate 6-O-endosulfatases (Sulfs) coordinate the Wnt signaling pathways to regulate myoblast fusion during skeletal muscle regeneration. J. Biol. Chem. 287, 32651–32664 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Nagai, N. et al. Involvement of heparan sulfate 6-O-sulfation in the regulation of energy metabolism and the alteration of thyroid hormone levels in male mice. Glycobiology 23, 980–992 (2013).

    CAS  PubMed  Google Scholar 

  52. 52.

    Vouillot, L., Thélie, A. & Pollet, N. Comparison of T7E1 and surveyor mismatch cleavage assays to detect mutations triggered by engineered nucleases. G3 (Bethesda) 5, 407–415 (2015).

    CAS  PubMed Central  Google Scholar 

  53. 53.

    Liu, W. et al. DSDecode: a web-based tool for decoding of sequencing chromatograms for genotyping of targeted mutations. Mol. Plant 8, 1431–1433 (2015).

    CAS  PubMed  Google Scholar 

  54. 54.

    Dehairs, J., Talebi, A., Cherifi, Y. & Swinnen, J. V. CRISP-ID: decoding CRISPR mediated indels by Sanger sequencing. Sci. Rep. 6, 28973 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  55. 55.

    Nairn, A. V. et al. Glycomics of proteoglycan biosynthesis in murine embryonic stem cell differentiation. J. Proteome Res. 6, 4374–4387 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Volpi, N. & Linhardt, R. J. High-performance liquid chromatography-mass spectrometry for mapping and sequencing glycosaminoglycan-derived oligosaccharides. Nat. Protoc. 5, 993–1004 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  57. 57.

    Skidmore, M. A., Guimond, S. E., Dumax-Vorzet, A. F., Yates, E. A. & Turnbull, J. E. Disaccharide compositional analysis of heparan sulfate and heparin polysaccharides using UV or high-sensitivity fluorescence (BODIPY) detection. Nat. Protoc. 5, 1983–1992 (2010).

    CAS  PubMed  Google Scholar 

  58. 58.

    Park, Y., Yu, G., Gunay, N. S. & Linhardt, R. J. Purification and characterization of heparan sulphate proteoglycan from bovine brain. Biochem. J. 344, 723–730 (1999).

    CAS  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Chen, Y., Reddy, M., Yu, Y., Zhang, F. & Linhardt, R. J. Glycosaminoglycans from chicken muscular stomach or gizzard. Glycoconj. J. 34, 119–126 (2017).

    CAS  PubMed  Google Scholar 

Download references


This research was supported by the NIH (R21HL131553, P41GM103390, 5R01HL093339, and U01CA225784 to L.W.; P01HL131474 and P01HL107150 to J.D.E.) and AHA (15POST21260001 and 17SDG33660550 to H.Q). S.S. and S.W. were supported by the Oversea Visiting Scholar Program for Middle-aged and Young Teachers in Shanghai Municipal Universities. We thank K. Howard for English-language revision of the manuscript. We also thank D. Bernsteel and H. Guo in the lab of M. Pierce at the University of Georgia (Athens, GA, USA) for providing the HT-29 cells, and J. Barber and J. Nelson in the flow cytometry core at the University of Georgia for their technical assistance.

Author information




H.Q. and L.W. conceived and designed the research and wrote the manuscript. H.Q. generated all the cell lines. H.Q., S.S., L.L., X.L., G.L., S.A.A.-H., S.W., P.A., F.Z., and R.J.L. designed and performed disaccharide analysis. R.J.L. also contributed to manuscript preparation. H.Q., M.X., and J.Y. performed western blotting. M.D.R., M.G., A.V.N., and K.W.M. performed the transcriptional analysis. T.H.v.K. provided the HS phage display antibodies and contributed to manuscript preparation. K.K., X.A., W.V.C., and J.D.E. provided the transgenic/knockout mice and contributed to manuscript preparation.

Corresponding author

Correspondence to Lianchun Wang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Integrated supplementary information

Supplementary Figure 1 Cre-loxP and CRISPR–Cas9 approaches to generate HS-mutant MLEC lines.

The primary MLECs were isolated from mice with HS genes systematically or conditionally targeted (loxP sites flanking the target gene, indicated by “floxed” or “f”). The primary MLECs were immortalized by expression of SV40 T antigen and then single-cell cloned to obtain MLEC lines. Next, the floxed gene was deleted by transient expression of Cre recombinase to derive the ‘daughter’ HS-mutant cell line. In addition, a ‘wild-type’ floxed (Ndst1f/f) MLEC line was cotransfected with target-gene-specific gRNA and Cas9 and then screened for the targeted gene insertion/deletion (indel) mutation and subjected to cell cloning to obtain HS-mutant cell lines. PAM, protospacer-adjacent motif.

Supplementary Figure 2 Expression of endothelial cell markers.

The generated MLEC lines were stained with anti-mouse CD31–FITC or VEGFR2–PE IgG antibody with the corresponding similarly fluorescein-labeled naive IgG staining as background control, and then subjected to flow cytometry analysis. The data shown are representative of 3 independent experiments.

Supplementary Figure 3 The expression patterns of HS biosynthetic and remodeling genes in additional immortalized wild-type MLEC lines.

The gene expression was quantified by qRT-PCR analysis with triplicate repeats. The data are presented as mean ± s.e.m. and are representative of 3 independent experiments.Extended Data. 3

Supplementary Figure 4 Characterization of CRISPR–Cas9-generated HS-mutant MLEC lines.

The Ndst1f/f MLECs were transiently cotransfected with plasmids encoding Cas9 and gRNA targeting Glce, Hs3st1, or Hs3st4 to derive Glce−/− (a), Hs3st1–/ – (b), and Hs3st4−/− (c) cell lines, respectively. The Hs3st1−/− cell line was transiently cotransfected with plasmids expressing Cas9 and gRNA targeting Hs3st4 to derive the Hs3st1−/−;Hs3st4−/− cell line (c). After puromycin selection, the transfected cells were cloned and screened by enzyme mismatch assay for gRNA-induced indel mutation. The identified indel mutations were further characterized by determination of the mutant nucleic acid sequences. Because of induced deletion larger than could be amplified by the PCR primers that amplify the gRNA-targeted region in the wild-type control, no gene sequencing data were obtained for Hs3st4 indels in the Hs3st4−/− and Hs3st1−/−;Hs3st4−/− MLEC lines. Representative results are shown as the mean ± s.e.m. of 3 independent PCR analyses.

Supplementary Figure 5 FGFR1–4 expression in MLEC lines.

(a). qRT-PCR analysis of FGFR1–4 mRNA expression in the wild-type MLEC lines. MLECs express both FGFR1 and FGFR2. Representative data from 3 independent experiments are presented as mean ± s.e.m. (b, c). Western blot analyses of FGFR1 and FGFR2 proteins. In the HS-mutant cell library, all 18 MLEC lines expressed only FGFR1. The human colorectal adenocarcinoma cell line HT29 was included as an FGFR2-expressing positive control. Beta-actin served as a loading control. Representative results from 3 independent western blot experiments are presented, and results of quantitation of the three independent experiments are shown as mean ± s.e.m.Extended Data. 5

Supplementary Figure 6 Whole gel from western blot analysis of FGFR1 and FGFR2 in MLEC lines.

Representative whole gels from three independent western blot analyses of FGFR1 and FGFR2 expression. The original data are presented in Supplementary Fig. 5.

Supplementary Figure 7 Western blot analysis of Erk phosphrylation in the MLEC lines after FGF2 stimulation.

Representative whole gels from three independent western blot analyses of FGFR1 and FGFR2 expression. The original data are presented in Supplementary Fig. 5.

Supplementary Figure 8 Western blot analysis of Erk1/2 phosphorylation in the MLEC lines after FGF2 stimulation.

The MLECs in triplicate were starved in serum-free DMEM for 1 h, stimulated with FGF at 5 ng/ml in serum-free DMEM for 15 min, and then lysed. The resultant cell lysates were analyzed to determine levels of p-Erk1/2 and Erk1/2 in western blots. Representative western blot data of three independent experiments are shown.

Supplementary Figure 9 Whole gels from western blot analysis of Erk phosphorylation in MLECs after FGF2 stimulation.

Whole gels from the western blot analysis of Erk phosphorylation after FGF2 stimulation. The original data are presented in Supplementary Fig. 8.

Supplementary Figure 10 Inter-regulation of HS biosynthesis by HS biosynthetic or remodeling genes.

The qRT-PCR data are representative of 3 independent experiments and are presented as mean ± s.d. P values as listed (two-sided, unpaired Student’s t-test).Extended Data. 10

Supplementary Figure 11 PAGE analysis of intact HS extracted from MLEC lines.

This experiment was carried out one time.

Supplementary information

Supplementary Text and Figures

Supplementary Figs. 1–11 and Supplementary Tables 1 and 2

Reporting Summary

Supplementary Data

Representative profile of the disaccharide composition of HS expressed in the mutant MLECs in HPLC analysis.

Source data

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Qiu, H., Shi, S., Yue, J. et al. A mutant-cell library for systematic analysis of heparan sulfate structure–function relationships. Nat Methods 15, 889–899 (2018). https://doi.org/10.1038/s41592-018-0189-6

Download citation

Further reading